Evaluation of Label Drug in the Treatment Polycystic Ovary Syndrome
- 10.2991/ahsr.k.200523.032How to use a DOI?
- off label, ovary, polycystic, syndrome
Objectives: Polycystic ovary syndrome (PCOS) is defined as high levels of hyperandrogenism, menstrual irregularities, anovulation and high levels of insulin (hyperinsulinemia secondary to increased insulin resistance).The estimated that> 75% of women with PCOS are insulin resistant, the incidence of PCOS affects 4% -8% of reproductive-aged women. The aims of this study to an evaluation of metformin treatment of PCOS. This research was a cross-sectional study with prospective data collection conducted From January to May 2019. Data from 16 participants were involved in this study, with the criteria inclusion. Data were processed statistically using Paired Sample T-test analysis to determine the effectiveness and side effects of metformin. There was a significant difference between the thickening of the endometrium before and after metformin treatment (P 0.001 <0.005). In observing the side effects, it was found that the use of metformin treatment was seen from random plasma glucose measurements on day 0, 3, 6 and 9 obtained (P 0.009<0.005) there were significant differences between the groups of random plasma glucose measurement days 0, 3, 6 and 9.
- © 2020, the Authors. Published by Atlantis Press.
- Open Access
- This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - CONF AU - Keni Idacahyati AU - Tita Nofianti AU - Ema Sintya Nurjaya PY - 2020 DA - 2020/06/08 TI - Evaluation of Label Drug in the Treatment Polycystic Ovary Syndrome BT - The proceedings of the 2nd Bakti Tunas Husada-Health Science International Conference (BTH-HSIC 2019) PB - Atlantis Press SP - 131 EP - 134 SN - 2468-5739 UR - https://doi.org/10.2991/ahsr.k.200523.032 DO - 10.2991/ahsr.k.200523.032 ID - Idacahyati2020 ER -